Previous 10 | Next 10 |
home / stock / rphm / rphm articles
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) shares initially traded higher Monday before turning negative after the company announced a proposed merg...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuti...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure's portfolio of novel precision medicin...
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition prop...
Shares of Ascent Industries Co. (NASDAQ: ACNT) rose sharply in pre-market trading as the company reported the sale of the business of Specialty Pi...
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.04% to 37,105.00 while...
Shares of Amtech Systems, Inc. (NASDAQ: ASYS) shares fell sharply during Thursday’s session after the company reported worse-than-expected f...
Reneo Pharmaceuticals Inc (NASDAQ: RPHM) shares are sinking after the company released data from its pivotal STRIDE Phase 2b study of mavodelp...
IRVINE, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM), a clinical stage pharmaceutical company focused on ...
News, Short Squeeze, Breakout and More Instantly...
Reneo Pharmaceuticals Inc. Company Name:
RPHM Stock Symbol:
NASDAQ Market:
Reneo Pharmaceuticals Inc. Website:
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sal...
MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM) (“Reneo”) with privately held OnKure, Inc. (“OnKure”) in a stock-for-stock transaction under which ...
Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing OnKure’s portfolio of novel precision medicines in oncology Combined company is expected to have approximately $120 million of cash resources at close, which is expected to provide fun...